Last reviewed · How we verify
FLIXOTIDE and SERETIDE
FLIXOTIDE (fluticasone propionate) is an inhaled corticosteroid that reduces airway inflammation, while SERETIDE combines fluticasone with salmeterol (a long-acting beta-2 agonist) to provide both anti-inflammatory and bronchodilator effects.
FLIXOTIDE (fluticasone propionate) is an inhaled corticosteroid that reduces airway inflammation, while SERETIDE combines fluticasone with salmeterol (a long-acting beta-2 agonist) to provide both anti-inflammatory and bronchodilator effects. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | FLIXOTIDE and SERETIDE |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid (FLIXOTIDE); Inhaled corticosteroid/long-acting beta-2 agonist combination (SERETIDE) |
| Target | Glucocorticoid receptor (fluticasone); Beta-2 adrenergic receptor (salmeterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate binds to glucocorticoid receptors in the lungs, suppressing inflammatory cytokine production and reducing airway edema and mucus secretion. Salmeterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and prolonging airway opening. Together in SERETIDE, they provide sustained control of asthma and COPD symptoms through complementary mechanisms.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Hoarseness
- Nervousness/anxiety
Key clinical trials
- Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation (PHASE3)
- A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma (PHASE3)
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
- Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139) (PHASE3)
- Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus® (PHASE3)
- Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler (NA)
- Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate (PHASE1)
- Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLIXOTIDE and SERETIDE CI brief — competitive landscape report
- FLIXOTIDE and SERETIDE updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI